Last reviewed · How we verify
KK8398
KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation.
KK8398 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 signaling pathway to reduce inflammatory cell recruitment and activation. Used for Autoimmune/inflammatory conditions (specific indication under investigation in phase 3).
At a glance
| Generic name | KK8398 |
|---|---|
| Sponsor | Kyowa Kirin Co., Ltd. |
| Drug class | Complement C5a receptor antagonist |
| Target | C5aR1 (C5a receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By antagonizing the C5a receptor (C5aR1), KK8398 inhibits complement-mediated inflammation, which plays a key role in various inflammatory and autoimmune diseases. This mechanism reduces the chemotactic activity of C5a, thereby decreasing neutrophil and other immune cell infiltration into affected tissues and limiting downstream inflammatory cascades.
Approved indications
- Autoimmune/inflammatory conditions (specific indication under investigation in phase 3)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KK8398 CI brief — competitive landscape report
- KK8398 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI